ARAY has had a very nice run over the past month or so. I've mistakenly held my position for years and I added to my position (on a whim) a couple months back and now am in with an average price in the mid-$5's. It's a very small position that I used to treat as a 'lesson holding', meaning it was there as a reminder that it's easy to lose money. Now I'm actually coming within striking distance of breaking even. Still made no sense to hold all this time, but I'd still like to come out ahead on this when all is said and done. Would appreciate others thoughts on ARAY.
New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
"Accuray Incorporated has added a news release to its Investor Relations website.
Title: New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Date(s): 20-Jul-2017 7:30 AM
For a complete listing of our news releases, please click here
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif., July 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a prospective study conducted at 14 French centers showed the clinical benefits of intensity-modulated radiation therapy (IMRT) delivered using the TomoTherapy® System over volumetric modulated arc therapy with RapidArc radiotherapy technology for patients with head and neck cancer. At 18 months, the local control rate and cancer-specific survival rate were significantly better in the TomoTherapy patient group than in the RapidArc group. The study, the first to prospectively compare clinical outcomes across radiation therapy platforms, was published online on June 26, 2017 in the peer-reviewed International Journal of Radiation Oncology - Biology - Physics.
The TomoTherapy System is the only radiation system specifically designed for image-guided IMRT. Its TomoHelicalTM Mode, used in this study, provides continuous delivery of radiation beams from 360 degrees around the patient, facilitating the treatment of the entire spectrum of head and neck tumors, regardless of shape or size or nodal involvement.
"This is the first study to assess whether the method of delivering IMRT impacts the results we are able to achieve. In previous studies, we showed that TomoHelical was able to deliver radiation dose distributions which precisely conformed to the shape of the tumor with steep radiation fall-off outside the target," said Jean-Emmanuel Bibault, MD, MSc, Department of Oncology and Radiotherapy, Georges-Pompidou European Hospital, Paris. "In this new study, we showed in a prospective, but not randomized manner, that this had a significant clinical impact. Precision and accuracy are especially important when treating head and neck tumors, where dose outside the desired target may result in damage to critical structures such as salivary glands, vocal cords, the spinal cord or brainstem. These results should be further explored in a randomized trial."
The study titled, "Clinical outcomes of several IMRT techniques for patients with head and neck cancer: A propensity score weighted analysis," provides results for 166 patients. It demonstrated:
The TomoTherapy System's unique ring-gantry based architecture and fast multileaf collimator, combined with its daily 3D image guidance, enabled clinicians to deliver a highly conformal and more homogeneous dose, contributing to better local control and cancer-specific survival rates compared to RapidArc Further analysis suggests an even greater benefit in the local control of larger tumors and those that have spread to a high number of lymph nodes Treatment with TomoHelical also enabled delivery of significantly reduced doses outside the tumor, leading to better acute salivary function than with RapidArc Mouth dryness assessed by the treated patients was worse in the RapidArc group Salivary disorders were more frequent in the RapidArc patient group "This landmark study demonstrates that the technique used to deliver IMRT can have a major impact on patient outcomes. Two key measures - the local control rate and cancer-specific survival rate - reinforce the TomoTherapy® System's effectiveness in managing head and neck tumors, results we would also expect to see with the RadixactTM System, our next-generation TomoTherapy platform. And, importantly, salivary function was compromised after treatment in significantly fewer patients treated with TomoTherapy, even while they achieved better tumor control," said Fabienne Hirigoyenberry-Lanson, VP Global Medical and Scientific Affairs of Accuray.
About the Study Fourteen institutions evaluated 166 patients in this prospective comparative study; 74 were treated using the TomoTherapy® System and 92 using RapidArc. Randomization was not possible because of unavailability of equipment. Inverse probability of treatment weighting (IPTW) using the propensity score analysis was undertaken to adjust for potential bias due to non-randomization. Even before the adjustment the TomoTherapy platform results were better than RapidArc as measured by local control, cancer-specific survival and salivary function, even though significant differences in several pre-treatment characteristics may have placed the TomoTherapy group at a disadvantage. Loco-regional control, specific and overall survival assessed 18 months after treatment were evaluated, as well as long-term toxicity and salivary function.
About Accuray Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements."
Precise, Innovative Tumor Treatments | Accuray
Accuray's radiation therapy and radiosurgery treatment solutions deliver exceptional patient experiences, build optimized workflows and achieve practice goals.
[!] Freshly upgraded to now include all available spread combinations - Option spread traders check out CreditSpreads.io, zero cost live feed of mathematically gainful option credit spreads for the coming month, sometimes including spreads for ARAY! High probability option credit spreads deliver a way to trade with specified risk and the max profit received right away. CreditSpreads.io lazer-targets only the spreads which meet its rigid requirements for risk and profit, and contributes to sustained profitability by warning you of any future catalysts which might affect the trade. http://www.creditspreads.io
Sustainable, high probability, defined risk stock option trading opportunities.
Montefiore is First in NY Metropolitan Area to Treat Cancer Patients with Accuray Radixact™ System
PR NewswireJune 27, 2017 Comment Cutting-Edge Radiation Therapy System Dramatically Improves Precision, Efficiency and Safety, While Minimizing Side Effects SUNNYVALE, Calif. and NEW YORK, June 27, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS), announced today that Montefiore doctors have treated the first cancer patients in New York with the advanced Radixact™ Treatment Delivery System. The system was designed to deliver image-guided intensity-modulated (IG-IMRT) radiation therapy, an extremely precise form of radiation therapy. Montefiore is the only hospital in New York State, and in the greater New York area, to have this equipment.
There is something in the wind ... I smell it
What do you know about the debt due in February 2018? How much? Who holds it?
Yahoo Finance Insights
ARAY is up 5.06% to 4.68
MicroCap SPECIAL ALERT to ARAY shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market. https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html
NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
When Levine took the helm in October 2012 the share price was over $7. Now it struggles to hang on to a $4 price. Down 43% in 5 years under this team. Value destruction. When will the board do something? Please!
Accuray Enters into New Revolving Loan Agreement
PR NewswireJune 15, 2017 Comment New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually SUNNYVALE, Calif., June 15, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it has closed a new $52 million senior secured revolving loan facility with MidCap Financial Trust. The net proceeds of the facility, in addition to cash on hand were used to retire all debt held by Cerberus Business Finance, LLC.
Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated) More The new facility bears interest at 90-day LIBOR (subject to a 1.00% floor) plus 450 basis points with a final maturity date of June 2021. This spread is up to 300 basis points lower than the debt being retired and as a result Accuray expects interest costs to be reduced by approximately $2.0 million annually beginning in fiscal 2018. The Company can draw upon a further $33.0 million of additional revolving facility, subject to the terms of the agreement. "The new agreement lowers our annual interest costs and reduces total debt outstanding by over $10.0 million," said Kevin Waters, Chief Financial Officer. "In regard to our remaining outstanding convertible debt, our objective remains to evaluate all financing sources that would allow us to either refinance our existing convertible debt or provide the cash necessary to settle the debt with cash at maturity and our new loan facility with MidCap Financial Trust gives us the flexibility to achieve that objective." The Company had $98.4 million of cash, cash equivalents, restricted cash and investments at March 31, 2017.
Anova Marks 1,500th Prostate Cancer Patient Treated with the Accuray CyberKnife® System
PR NewswireJune 16, 2017 Comment - Accuray and Anova Cancer Care Remember Prostate Patients this Father's Day - CyberKnife System Provides Grandfathers, Fathers, Brothers, Uncles and Sons with Precise Radiation Treatments in Fewer Treatment Sessions than Conventional Radiation Therapy SUNNYVALE, Calif., June 16, 2017 /PRNewswire/ -- In honor of Father's Day, Accuray Incorporated (ARAY) joins Anova Cancer Care in recognizing the center's commitment to providing the most advanced treatments available to men with prostate cancer, many of whom are fathers. The center, located in Lone Tree, Colorado, has treated its 1,500th prostate cancer patient using the CyberKnife® System—an advanced radiation therapy device designed to deliver stereotactic body radiation therapy (SBRT). SBRT is a highly precise form of radiation therapy which maximizes dose to the tumor and minimizes dose to surrounding healthy tissue. According to the American Cancer Society, more than 161,000 men will be diagnosed with prostate cancer in 2017. It's important for men to take action to improve their health, including learning about medical conditions which specifically impact them, like prostate cancer, and options for managing the disease. This Father's Day, June 18, 2017, men and their families can learn about prostate cancer at rallies held by:
Yahoo Finance Insights
ARAY is up 5.49% to 4.32
I wonder what became of China's Class A license's
Urgent message to ARAY's Board of Directors: Take the company private! It's obvious that ARAY is NOT going to be taken over or it would have happened already. IMHO, the next best thing to a takeover would be for Accuray to take the company private. The department store, Nordstrom, which has been struggling like many other retailers, announced today that they are pursuing plans to take the company private, and the price per share jumped over 10%. I am naive to think that if enough ARAY shareholders voiced to management the idea of taking the company private, maybe they might actually do it. I am keeping my fingers crossed. Sincerely, a long-term, frustrated, Accuray shareholder. I would welcome any feedback on the idea of taking the company private.
Accuray Appoints Stan Gee VP of Revenue Management
PR NewswireMay 24, 2017 Comment SUNNYVALE, Calif., May 24, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it has appointed, Stan Gee, who has been with Accuray for over eight years, to the newly created Vice President of Revenue Management position reporting to Kevin Waters, Chief Financial Officer. Mr. Gee will be responsible for driving the global revenue forecast and overseeing the order to revenue conversion process for the Company. In his new role, Mr. Gee will be working closely with Accuray's customers, regional installation, service and commercial teams to improve the overall timing and cadence of system installation and ultimately revenue conversion, specifically in those regions where distributor initiated orders have become a bigger part of the overall order mix in backlog.
Yahoo Finance Insights
ARAY is down -5.17% to 4.13
The upside potential for ARAY just got a whole lot more interesting. have you guys heard of awesome.stocks. i started receiving their allerts and so far i am happy.
Increase in share price wondering why. The stock seems to be accumulated slowly.
ARAY price seems to be at its base ... $4 ... with some sort of speculation going on in the $4.05 to $4.15 range, as buyers pick up bits here and there.
And, continuing my comment of yesterday ... as high as $4.28 ...hmmmm ... what's up?